Significance of HBV NAT Among HBs Antigen–Negative Blood Donors in Saudi Arabia

Alabdallat, Nessrin Ghazi; Dukhyil, Abdul Aziz A Bin

doi:10.1093/labmed/lmy023

Cited by 7 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OBI has the following clinical implications: (i) HBV transmission by transfusion of blood products or by liver transplantation, (ii) HBV reactivation with consequent development of hepatitis B, as in cases undergoing potent immune-suppressive or chemotherapeutic therapies. Whereas, NAT for HBV has become a routine part of blood-donor infectious-disease screening in other parts of the world, developing countries such as Kenya still lag behind ( 100 ). In our review, only two out of the fifty studies examined HBV DNA by real-time PCR in the HBsAg negative population ( 65 , 76 ).…”

Section: Discussionmentioning

confidence: 99%

The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis

Makokha

Zhang

Hayes

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

BackgroundChronic Hepatitis B virus (HBV) infection causes liver cirrhosis and cancer and is a major public health concern in Kenya. However, so far no systematic review and meta-analysis has been conducted to estimate the burden of disease in the country. A better understanding of HBV infection prevalence will help the government implement efficient strategies at eliminating the disease. This systematic review and meta-analysis was therefore conducted to summarize and update the available information on the burden of HBV in Kenya.MethodWe systematically searched PubMed, Science Direct, Web of Science, Scopus, African Journals OnLine, and Google Scholar databases to retrieve primary studies conducted between January 1990 and June 2021 that assessed the prevalence of HBV infection in Kenya based on measurement of the Hepatitis B Surface Antigen (HBsAg). Meta-analysis was performed using the random effects model where HBsAg prevalence was estimated at a 95% confidence interval (CI) after simple pooling analysis. Potential sources of heterogeneity were also investigated.ResultsFifty studies were included in the meta-analysis with a sample size of 108448. The overall pooled prevalence estimate of HBV in Kenya was 7.8% (95% CI: 5.8–10.1). Subgroup analysis revealed the highest prevalence among patients presenting with jaundice at 41.7% (95% CI: 13.5–73.3) whereas blood donors had the lowest prevalence at 4.1% (95% CI: 2.4–6.3). Prevalence in Human Immunodeficiency Virus (HIV)-infected individuals was 8.2% (95% CI: 5.8–11.0). An estimate of the total variation between studies revealed substantial heterogeneity (I2 = 99%) which could be explained by the study type, the risk status of individuals, and the region of study.ConclusionWe present the first systematic review and meta-analysis of the prevalence of HBV in Kenya. Our results show that the burden of HBV in Kenya is still enormous. This calls for an urgent need to implement public health intervention measures and strategic policies that will bring the disease under control and lead to final elimination.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=264859, identifier: CRD42021264859.

show abstract

Section: Discussionmentioning

confidence: 99%

The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis

Makokha

Zhang

Hayes

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…NAT positive results along with anti-HBc highlights the use of both these markers to eliminate any potential risk of HBV transmission thorough blood transfusion. The importance of NAT utilization in donor screening has been authenticated by several studies [ 16 , 31 ]. This study shows that the results of positive HBV, within 2 years period, did not show any difference.…”

Section: Discussionmentioning

confidence: 99%

Patterns of Hepatitis B, Hepatitis C and HIV Among Blood Donors in Samtah-Jazan Region

Madkhali

Dobie

Saboor

et al. 2022

J Epidemiol Glob Health

View full text Add to dashboard Cite

Background and Objective Transfusion-transmitted infectious agents are amongst the major health burden worldwide. The purpose of this study was to evaluate the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) among blood donors in Samtah General Hospital, Jazan region, Saudi Arabia. Material and Methods In this retrospective study, blood donation records of all blood donors recruited between January 2019 and August 2020 were included for data acquisition. A total of 4977 blood donors’ records were reviewed and data were analysed. Results Hepatitis B profile showed 0.60% blood donors positive for hepatis B surface antigen (HBsAg). Nucleic acid testing (NAT) showed the presence of HBV-DNA in 0.4% of the blood donors. Anti-HBs and anti-HBc antibodies were reactive in 3.34% and 7.31% blood donors’ units, respectively. Anti-HCV antibodies were reactive among 54 (1.09%) blood donors. Upon reviewing the NAT analysis results, 0.16% (08) blood donors showed the presence of HCV-RNA in their blood units. Anti-HIV antibodies were reactive in 8 (0.16%) blood donors. Conclusion It is concluded that the frequency of HBsAg is comparatively lower while anti-HCV positivity is higher in Samtah, Jazan as a region compared to other regions of the country. Further studies are warranted to evaluate the cause of HCV infection in this area. Frequency of HIV is uncommon in this area.

show abstract

“…These screening tests based on the measurement of HBV specific antigen and antibodies found in specimens, are performed to determine acute or chronic and current or past infections [8]. However, drug resistance mutations, occult infections as well as low level of HBsAg and viral load values during window period of HBV infections may be undetectable by using one or combination of these serological tests [9][10][11][12]. To validate HBV infection and follow up the chronic patients, nucleic acid-based detection assays that quantify viral HBV DNA, determine drug resistance mutations, occult and window period HBV infections in clinical samples, have been widely employed [11,12].…”

Section: Introductionmentioning

confidence: 99%

NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples

Arıkan

Sayan

Doluca

2020

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Currently, several molecular assays are available to detect and quantify HBV DNA in clinical samples. We aimed to characterize and compare the clinical performance of newly designed NeuMoDx PCR to the existing artus PCR. Methodology: The plasma HBV DNA levels of 96 clinical and 5 external quality control samples were measured by NeuMoDx and artus assays simultaneously in Kocaeli University, Turkey. The linearity, agreement and the correlation between two assays were determined by Deming regression analysis, Bland-Altman plotting, the chi-square and the relative absolute error statistical analyzes. For all statistical analyzes, the XLSTAT statistical program was used. Results: The mean (standard deviation; SD) age was 45.07 ± 12.29. HBsAg S/Co median (range) was 4,273.4 ± 1,138.1 and ALT U/L median (range) was 27 ± 16. The mean (SD) of HBV DNA was 1.46+E6 ± 1.0+E4 for NeuMoDx and 1.54+E5 ± 4.7 + E4 for artus assays. The Deming regression indicates a linear correlation (95% confidence). The chi-square test indicates strong correlation (p < 0.001). Bland-Altman analysis confirms that the measurement difference is acceptable. The relative absolute error analysis for artus showed relatively less and more consistent error rate. With 5 external quality check samples, the statistical significance was low (p = 0.566). Conclusions: The NeuMoDx HBV assay showed an excellent analytical performance by providing a rapid, high throughput technology in a random-access testing system in clinical samples and may be a new solution for viral load quantification in the management of HBV infections.

show abstract

Significance of HBV NAT Among HBs Antigen–Negative Blood Donors in Saudi Arabia

Abstract: The frequency of HBV DNA in blood donors who tested seronegative was low. This finding may indicate the significance of the HBV NAT technique in reducing the residual risk of transfusion-transmitted HBV infection.

Cited by 7 publications

References 22 publications

The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis

The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis

Patterns of Hepatitis B, Hepatitis C and HIV Among Blood Donors in Samtah-Jazan Region

NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples

Contact Info

Product

Resources

About